close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Iovance Biotherapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Present at Upcoming Conference
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today